Global Phase 3 Program Expected to Commence Before End of Q3 2017 International Phase 3 Trials Entitled “ULTIMATE I” and “ULTIMATE II” to be Led by Lawrence Steinman, MD, of Stanford University NEW ...
SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase 3 trials for the subcutaneous formulation set to begin later in Q2 2025. Additionally, enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback